Case ReportIntravitreal Bevacizumab (Avastin) Injection for Neovascular GlaucomaYazdani, Shahin MD; Hendi, Kamran MD; Pakravan, Mohammad MD Author Information Ophthalmic Research Center and Department of Ophthalmology, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran The authors have no financial or proprietary interest in any material or method mentioned in this report. Reprints: Shahin Yazdani, MD, Ophthalmic Research Center, Labbafinejad Medical Center, Boostan 9 Street, Pasdaran Avenue, Tehran 16666, Iran (e-mail: [email protected]). Received for publication June 21, 2006; accepted February 5, 2007 Journal of Glaucoma: August 2007 - Volume 16 - Issue 5 - p 437-439 doi: 10.1097/IJG.0b013e3180457c47 Buy Metrics Abstract Neovascular glaucoma is a secondary glaucoma with grave prognosis which follows ischemic retinal disorders in the majority of cases. Mediators that induce new vessel formation such as the vascular endothelial growth factor-A seem to play a key role in the pathophysiology of this condition. Herein, we report 2 cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion who received treatment with intravitreal bevacizumab (Avastin) a nonselective antibody against vascular endothelial growth factor-A. Both patients demonstrated dramatic short-term response in terms of intraocular pressure reduction and regression of neovascularization. © 2007 Lippincott Williams & Wilkins, Inc.